Company Projected Revenue: OS Therapies Inc (OSTX)

Corporate emblem and logo of OS Therapies Inc. (OSTX)

OS Therapies Incorporated (OSTX) is developing a portfolio of osteosarcoma drugs, seeking partnerships with industry behemoths. The business model relies on patents, which will ensure high margins through outsourced production. The company's sales volume forecasts confirm market expectations, where the latest parameter is 0.00. The issuer's success depends on drug test results and obtaining orphan drug status.

ostherapies.com - OSTX Company Future Revenue (period 08/02/2024 - 11/17/2026)

Financial and market metric breakdowns for OS Therapies Inc (OSTX)

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:OSTX OS Therapies
Brand item of OS Therapies Inc.

The development of immunotherapy for the treatment of osteosarcoma drives the revenue expectations for OS Therapies Incorporated (OSTX). This indicator reflects the market capitalization of the issuer's rights to future cash flows. The calculation is based on the discounting of projected vaccine sales revenues through insurance funds. The growth of this metric confirms investor confidence in the commercial success of the drugs, allowing speculative noise to be separated from the actual fundamental trend.

Direct competitors

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Company Projected Revenue ymabs.com (YMAB)|Company Projected Revenue AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Company Future Sales Volume|Accuray Inc. (ARAY) - Company Expected Sales Volume|SELLAS Life Sciences Group, Inc. - Projected Sales Volume|Company Future Revenue ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Company Projected Revenue|HURA - Company Future Sales|TARA (Protara Therapeutics, Inc.) - Projected Sales Volume|Projected Sales Volume Fate Therapeutics Inc|Projected Sales Volume WHWK|Projected Sales Volume TScan Therapeutics Inc (TCRX)|Company Projected Revenue championsoncology.com CSBR|XBIT - Company Future Sales Volume|CVM - Company Projected Revenue|Company Future Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Projected Revenue|ANL: Company Projected Revenue Volume|VERU (Veru Corporation) - Projected Sales Volume|Company Expected Sales Volume Tempest Therapeutics, Inc. TPST|Projected Sales Volume XLO|Renovaro - Company Revenue Forecast|Company Projected Revenue Mural Bio MURA|KAPA: Company Revenue Forecast|OnKure Therapeutics - Projected Sales Volume|Company Future Sales w2.cytomed.sg GDTC|CRIS: Projected Sales Volume|Company Future Sales Volume Apollomics Inc.|THAR (Tharimmune Corporation) - Projected Sales Volume|Projected Sales Volume Advanced Biomed Inc|Projected Sales Volume GNPX|Company Future Sales Volume Calidi Biotherapeutics Inc. CLDI|Company Projected Revenue Sunshine Biopharma Inc. SBFM|Company Future Sales Xenetic Biosciences (XBIO)|SLRX - Company Projected Revenue|Company Expected Sales Volume Kitov Pharma|AON (AONC) - Company Projected Revenue|Company Future Sales Volume BeiGene|Company Projected Revenue checkpointtx.com|Company Revenue Forecast ELEV (Elevation Oncology)|Projected Sales Volume ICAD|Ikena Oncology - Company Revenue Forecast|Company Projected Revenue Notable Labs, Ltd. NTBL|VIRX: Company Revenue Forecast|MOR - Company Projected Revenue|NAYA Bio (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume